INDICATIONS FOR ANASTROZOL USE
The first line of treatment for a locally prevalent breast tumour, with unknown or positive hormone receptors in the postmenopause. Adjuvant therapy for early breast cancer with positive hormonal receptors in the postmenopause. Therapy for common breast cancer after tamoxifen treatment (second line).
METHOD OF APPLICATION AND DOSES
Adults, including elderly patients, are taken orally (inwards, with water) 1 mg once a day for the same length of time. If signs of disease progression appear, it is advisable to stop taking the drug.
When taking anastrozol simultaneously with other frequently prescribed medications, no threatening drug interaction has been detected, in particular no information on the use of the medication in combination with other antitumoral medications. Medicines containing estrogens reduce the pharmacological effect of anastrozole, so they should not be administered at the same time as anastrozole. Tamoxifen should not be administered at the same time as anastrozole due to the reduced pharmacological effect.
Uterine bleeding is possible against the background of taking anastrozole. In this case, a consultation and supervision by a gynaecologist is necessary. In addition, the hormonal status of the patient must be confirmed. Menopause is determined by the concentration of sex hormones in the blood serum.
In osteoporosis, the mineral density of bone tissue is assessed at the beginning and regularly during treatment by densitometry, e.g. by DEXA-scanning (two-energy X-ray absorption). If necessary, therapeutic and preventive procedures should be carried out and the patient's condition monitored carefully. As Anastrozol-Teva reduces the concentration of circulating estradiol, this may lead to a decrease in the mineral density of bone tissue. There is no evidence of simultaneous use of anastrozole and GnRH analogues. When women have a receptor-negative tumour to estrogen, the effectiveness of anastrozol has not been observed unless there has been previous positive clinical experience with tamoxifen. Preparations containing estrogens should not be administered at the same time as Anastrozol-Teva, as they have a negative effect on its pharmacological effect.
The efficacy and safety of anastrozole and tamoxifen when used at the same time, regardless of the status of hormone receptors, are comparable to those of a single tamoxifen. The exact mechanism of this phenomenon is not yet known. The positive effect of anastrozole treatment when combined with chemotherapy has not been proven.
It affects the ability to drive. Side effects such as asthenia and drowsiness when taking anastrozole may have a negative impact on potentially dangerous activities that require increased concentration and speed of psychomotor reactions. Caution is recommended when these symptoms appear.
The antitumour drug Anastrozol-Teva is prescribed to patients in the treatment of breast cancer. It is also used after adjuvant tamoxifen therapy for 2-3 years. The drug is active in the treatment of estrogen-dependent breast tumours. The growth of this type of tumour in women in the postmenopause period is influenced by estradiol. It can also be used to treat elderly people, and the dosage for them is maintained. The drug is very effective, so I often prescribe it to my patients. As adjuvant therapy, treatment with Anastrozol-Tev should last for 5 years, with periodic dose adjustment and monitoring of the woman's condition.
In order to reduce the risk of adverse reactions, I recommend taking the drug without interruption, at the same time. Women should not drive during treatment, as the speed of reactions decreases. Some patients experience drowsiness and asthenia during Anastrozol-Tev, which disappear when they stop taking the medicine.
|Active ingredient, mg||1|
|1 pill, mg||1|
|Blister, pills||2, 14|
|Packing||Blister (14 pills), Packing (2 blisters)|
There are no reviews for this product.